Navigation Links
Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
Date:5/8/2009

Approximately 60 Percent of Patients Reached American Diabetes Association's Recommended Average Blood Sugar Level

PRINCETON, N.J., May 8 /PRNewswire/ -- Novo Nordisk today announced results from the TITRATE(R) study showing that Levemir(R) (insulin detemir [rDNA origin] injection), taken once-daily, substantially lowered average blood sugar. Type 2 diabetes patients took a more active role in their treatment by adjusting their own dosing, after being trained and given an adjustment schedule by their physician. Approximately 60 percent of patients taking Levemir(R) once-daily reached the American Diabetes Association's (ADA) recommended average blood sugar level.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novonordisk/38372/

"Teaching and empowering patients to adjust their own insulin doses can help them achieve good blood sugar control," said Lawrence Blonde, MD, Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism at the Ochsner Medical Center, New Orleans and the lead researcher in the trial. "These findings showed that following a self-adjustment dosing schedule of Levemir(R) once-daily resulted in a majority of patients reaching the target blood sugar level that the ADA recommends for most patients."

The TITRATE(R) study was published this week online in the journal, Diabetes, Obesity & Metabolism.

Patients who had not previously used insulin and had a starting average blood sugar level (A1C) of less than 9 percent, adjusted their dose of Levemir(R) to reach specific fasting blood sugar targets of 70-90 mg/dL or 80-110 mg/dL. Fasting blood sugar is the amount of sugar in the blood as determined by a blood test (called FPG) taken first thing in the morning after not eating for at least 8 hours. The study showed that Levemir(R) taken once-daily substantially lowered patients' A1C levels after 20 weeks for both FPG targets tested.

In the study, 64.3 percent of patients in the 70-90 mg/dL FPG target treatment group and 54.5 percent of patients in the 80-110 mg/dL FPG target group reached the ADA recommended A1C level of less than 7 percent. A1C levels in the 70-90 mg/dL group decreased by 1.2 percent to an average A1C of 6.77 percent; A1C levels in the 80-110 mg/dL group decreased by 0.9 percent to an average A1C level of 7 percent.

"Good blood sugar control is important in managing diabetes, and the more active a role patients can play, the better," said Alan Moses, Vice President and Global Chief Medical Officer at Novo Nordisk. "This study is exciting because it showed that Levemir(R) at a once-daily dose helped these patients manage their condition, and in doing so, helped them achieve substantial A1C reductions."

Rates of minor hypoglycemic events were low and comparable between the two treatment groups (5.09 vs 3.16 events/patient/year in the 70-90 mg/dL and 80-110 mg/dL FPG target treatment groups, respectively). A single major hypoglycemic event (requiring third party assistance) was reported by a patient in the 70-90 mg/dL FPG target treatment group. More details about the study can be found in the journal. Prescribing information for Levemir(R) is available by contacting Novo Nordisk or visiting novonordisk-us.com.

About the Study

The open-label TITRATE(R) study was a prospective, randomized, controlled study to examine the effect of patients self dosing of Levemir(R) once-daily using two FPG targets on blood sugar control. In the study, 244 type 2 diabetes patients taking oral antidiabetes drugs, who had never before used insulin, were assigned to one of two treatment groups: using 70-90 mg/dL or 80-110 mg/dL as their fasting blood sugar targets. After being trained and given an adjustment schedule by their physician, patients continued their use of oral diabetes drugs and changed their insulin dose every three days. Levemir(R) was initiated at 0.1 to 0.2 unit/kg or 10 units once-daily at dinner or bedtime.

About Levemir(R) (insulin detemir [rDNA origin] injection)

Levemir(R) is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir(R) is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir(R). As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir(R) is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir(R) should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir(R) from other intermediate or long-acting insulin preparations. The dose of Levemir(R) may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3 percent to 4 percent of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation. Less common, but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.

Levemir(R) is a registered trademark of Novo Nordisk A/S.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit www.novonordisk-us.com.

For more information on the Ochsner Medical Center, go to www.ochsner.org.

(C) Novo Nordisk Inc. 137944 May 2009


'/>"/>
SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
2. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
3. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
4. Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity
5. Photo: Introducing a New Line of Baby and Toddler Shirts that Can Help Protect Innocent Babies During Flu Season
6. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
7. Photo: New York Goes Orange for Pumpkin Festival and Lupus Awareness Month
8. Photo: Scientists Complete Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders
9. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
10. Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles
11. Photo: KFC Colonel Original and Look-a-Like Share Eye Treatment Success Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... , ... Johns Hopkins All Children's Hospital celebrated a major milestone with the ... marked the halfway point of construction and lifting of the final beam on the ... a center for innovation aimed at finding new discoveries and treatments for childhood diseases. ...
(Date:2/19/2017)... ... , ... Braun Industries will be participating as an exhibitor at EMS Today ... February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt ... ambulances on display. , “JEMS is a leader in EMS news and ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... of disruptive innovation in the industry, according to the recent NEJM Catalyst Insights ... on surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
Breaking Medicine Technology: